Roche Breast Cancer Drug Gets FDA Priority Review

Published: Feb 10, 2012

Roche Holding AG Wednesday said the U.S. Food and Drug Administration has accepted the company's Biologics License Application for pertuzumab and granted Priority Review. MAIN FACTS: - The proposed indication is pertuzumab in combination with Herceptin (trastuzumab) and docetaxel chemotherapy for people with HER2-positive metastatic or locally recurrent, unresectable breast cancer, who have not received previous treatment or whose disease has relapsed after adjuvant therapy.

Back to news